Recent advances in cellular therapy for malignant lymphoma.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 33558145.
- Also identified by DOI 10.1016/j.jcyt.2020.12.007.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cellular therapies for malignant lymphoma include autologous or allogeneic hematopoietic stem cell transplantation (HSCT) and adaptive cellular therapy using EBV-specific T cells, cytokine-induced killer (CIK) cells, NKT cells, NK cells, chimeric antigen receptor T (CAR-T) cells and chimeric antigen receptor NK (CAR-NK) cells. In this review we discusses recent advances of these cellular therapies and consider ways to optimize these therapies. Not only a single strategy using one of these cellular therapies, but also multi-disciplinary treatment combines with antibodies, such as an anti-tumor antibody and an immune checkpoint antibody, may be more effective for relapsed and refractory lymphoma.
Medical subject headings
- Cytokine-Induced Killer Cells
- Hematopoietic Stem Cell Transplantation
- Lymphoma
- Receptors, Chimeric Antigen